hu-308 and Acute-Lung-Injury

hu-308 has been researched along with Acute-Lung-Injury* in 3 studies

Other Studies

3 other study(ies) available for hu-308 and Acute-Lung-Injury

ArticleYear
Cannabinoid receptor 2 alleviates sepsis-associated acute lung injury by modulating maturation of dendritic cells.
    International immunopharmacology, 2023, Volume: 123

    Dendritic cells (DCs) play a key role in a variety of inflammatory lung diseases, but their role in sepsis-associated acute lung injury (SA-ALI) is currently not been illuminated. Cannabinoid receptor 2 (CNR2) has been reported to regulate the DCs maturation. However, whether the CNR2 in DCs contributes to therapeutic therapy for SA-ALI remain unclear. In current study, the role of CNR2 on DCs maturation and inflammatory during SA-ALI is to explored.. First, the CNR2 level was analyzed in isolated Peripheral Blood Mononuclear Cells (PBMCs) and Bronchoalveolar Lavage Fluid (BALF) from patient with SA-ALI by qRT-PCR and flow cytometry. Subsequently, HU308, a specific agonist of CNR2, and SR144528, a specific antagonist of CNR2, were introduced to explore the function of CNR2 on DCs maturation and inflammatory during SA-ALI. Finally, CNR2 conditional knockout mice were generated to further confirm the function of DCs maturation and Inflammation during SA-ALI.. First, we found that the expression of CNR2 on DCs was decreased in patient with SA-ALI. Besides, the result showed HU308 could decrease the maturation of DCs and the level of inflammatory cytokines, simultaneously reduce pulmonary pathological injury after LPS-induced sepsis in mice. In contrast of HU308, SR144528 exhibits opposite function of DCs maturate, inflammatory cytokines and lung pathological injury. Furthermore, comparing with SR144528 treatment, similar results were obtained in DCs specific CNR2 knockout mice after LPS treatment.. CNR2 could alleviate SA-ALI by modulating maturation of DCs and inflammatory factors levels. Targeting CNR2 signaling specifically in DCs has therapeutic potential for the treatment of SA-ALI.

    Topics: Acute Lung Injury; Animals; Cytokines; Dendritic Cells; Humans; Leukocytes, Mononuclear; Lipopolysaccharides; Lung; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, Cannabinoid; Sepsis

2023
Selective CB
    International journal of molecular sciences, 2022, Dec-13, Volume: 23, Issue:24

    Topics: Acute Lung Injury; Animals; Cannabinoids; Cytokines; Dexamethasone; Endotoxins; Inflammation; Lipopolysaccharides; Lung; Mice; Mice, Inbred C57BL; Microcirculation; Pneumonia; Respiratory Distress Syndrome; Sepsis

2022
Cannabinoid receptor 2 activation alleviates septic lung injury by promoting autophagy via inhibition of inflammatory mediator release.
    Cellular signalling, 2020, Volume: 69

    Septic lung injury is one of main causes of high mortality in severe patients. Inhibition of excessive inflammatory response is considered as an effective strategy for septic lung injury. Previous studies have shown that cannabinoid receptor 2 (CB2), a G protein-coupled receptor, play an important role in immunosuppression. Whether CB2 can be used as a therapeutic target for septic lung injury is unclear. The aim of this study is to explore the role of CB2 in sepsis and its potential mechanism. In this study, treatment with HU308, a specific agonist of CB2, could reduce lung pathological injury, decrease the level of inflammatory cytokines and strengthen the expression of autophagy-related gene after cecal ligation puncture (CLP)-induced sepsis in mice. Similar results were obtained in RAW264.7 macrophages after LPS treatment. Furthermore, the effect of HU308 could be blocked by autophagy blocker 3-MA in vivo and in vitro. These results suggest that CB2 serves as a protective target for septic lung injury by decreasing inflammatory factors, which is associated with the enhancement of autophagy.

    Topics: Acute Lung Injury; Animals; Autophagy; Cannabinoid Receptor Agonists; Cannabinoids; Cytokines; Immunosuppression Therapy; Inflammation Mediators; Male; Mice; Mice, Inbred C57BL; RAW 264.7 Cells; Receptor, Cannabinoid, CB2; Sepsis

2020